Suchergebnisse - "Wuerstlein, Rachel"

PubPharm (10)

1

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer : The Neoadjuvant WSG-TP-II Randomized Clinical Trial

enthalten in: JAMA oncology | 2023

von Gluz, O. | Nitz, U. | Christgen, M. | +17

2

The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C

enthalten in: British journal of cancer | 2022

von de Gregorio, A. | Janni, W. | Friedl, T. | +17

3

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer

enthalten in: Cancer medicine | 2021

von Grote, I. | Bartels, S. | Kandt, L. | +20

4

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Robertson, J. | Evans, A. | Henschen, S. | +24

5

Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial

enthalten in: Breast cancer research : BCR | 2020

von Kolberg-Liedtke, C. | Gluz, O. | Heinisch, F. | +13

6

Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer

enthalten in: Breast cancer research and treatment | 2019

von Wunderle, M. | Pretscher, J. | Brucker, S. | +47

7

Truly personalized therapy - an end to the era of one size fits all

enthalten in: Nature reviews. Clinical oncology | 2019

von Harbeck, N. | Wuerstlein, R.

8

Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry

enthalten in: Breast (Edinburgh, Scotland) | 2018

von Hartkopf, A. | Huober, J. | Volz, B. | +30

9

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC) : Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2017

von Harbeck, N. | Gluz, O. | Christgen, M. | +18

10

Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer : evidence and clinical considerations

enthalten in: Drugs | 2013

von Harbeck, N. | Wuerstlein, R.

1
[1]